Company Interview / Reflux to result: Proteomics' non-invasive cancer test

Dr Richard Lipscombe from Proteomics International (ASX:PIQ) shares their new non-invasive diagnostic tool, Promarker. This blood test targets individuals with chronic acid reflux, a precursor to esophageal adenocarcinoma, aiming to offer a less invasive alternative to endoscopy, which is costly and uncomfortable.

Richard highlights that their clinical validation studies, involving nearly 300 patients, demonstrate the test's accuracy. With regulatory pathways in Australia and the US, they're poised to introduce the esophageal cancer test to both markets this year, alongside a diagnostic blood test for endometriosis, affecting 1 in 9 women worldwide.

On the financial front, Proteomics (ASX:PIQ) International has successfully raised $12 million to support the rollout of these innovative tests. Richard notes the strong response from shareholders to the share purchase plan, enabling accelerated marketing and user engagement efforts.